IDO rout: Piv­otal tri­als with Bris­tol-My­ers, Mer­ck and As­traZeneca dumped in wake of In­cyte's PhI­II im­plo­sion

8 years ago
R&D

Karyopharm stock soars on se­linex­or's pos­i­tive PhI­Ib up­date, plans for an NDA

8 years ago
R&D

Eye­ing Eylea's $5B sales, No­var­tis touts sol­id 12-week dos­ing da­ta for its ri­val RTH258

8 years ago
R&D

Two biotechs hunt $175 mil­lion in Nas­daq pur­suit; Keryx CEO Gre­go­ry Madi­son abrupt­ly re­signs; Rx­Cel­er­ate buys ...

8 years ago
News Briefing

Al­ler­gan's $639M Vi­tae buy­out is a bust. R&D writes off their pso­ri­a­sis pro­gram as a com­plete loss

8 years ago
R&D

Spark's PRV draws luke­warm price, sell­ing for $110M to Jazz

8 years ago
Pharma

Leena Gand­hi steps out of Keytru­da spot­light and in­to a top re­search job at I/O lag­gard Eli Lil­ly

8 years ago
People

IL-2 with­out the tox­ic side ef­fects? Or­bimed backs the idea in Syn­thorx' $63M round

8 years ago
Financing
Startups

Who’s the top earn­ing CEO in bio­phar­ma? Mar­tine Roth­blatt once again hits top slot with $37M pay pack­age

8 years ago
People

Unit­ed Ther­a­peu­tics bags ri­val SteadyMed for a bar­gain base­ment deal worth up to $216M, elim­i­nat­ing patent threat

8 years ago
Deals

What do you get when you in­te­grate health­care da­ta from mul­ti­ple sources in­to one com­pre­hen­sive, glob­al pack­age? ...

8 years ago
Financing
Deals

Re­gen­eron/Sanofi cir­cle Oc­to­ber 28 on the cal­en­dar as the FDA be­gins a speedy re­view of the world’s 6th PD-1/L1 ...

8 years ago
Pharma

Crescen­do snares $70M Se­ries B for its tu­mor-fight­ing tech

8 years ago
Financing

Alzheon steps back from an IPO, fur­ther than ever from a PhI­II Alzheimer’s study

8 years ago
Financing

Eye­ing block­buster mi­graine mar­ket, Al­ler­gan un­loads sec­ond set of pos­i­tive PhI­II re­sults for ubro­gepant

8 years ago
R&D

Ahead of Hong Kong list­ing changes, WuXi preps for a biotech boom with a new R&D cen­ter in Shang­hai

8 years ago
R&D
China

IPO plans brew­ing, In­novent Bi­o­log­ics rais­es $150M and eyes hun­dreds of mil­lions more

8 years ago
Financing

Ex-As­traZeneca ex­ec Lisa An­son to lead do-over at Redx; Ad­vax­is shakes up C-suite

8 years ago
Peer Review

Two more top FDA of­fi­cials hit the ex­its as an ex­o­dus of se­nior reg­u­la­tors con­tin­ues

8 years ago
People
Pharma

Ver­tex's rapid-fire PhI­II pro­gram hits a road­block at the FDA. Will reg­u­la­tors force ri­val Gala­pa­gos to slow down ...

8 years ago
Pharma

Alex­ion preps an FDA pitch on Soliris suc­ces­sor while sig­nal­ing more deals ahead for rare dis­ease drugs

8 years ago
R&D

CRISPR leg­end Jen­nifer Doud­na helps some re­cent col­lege grads launch a di­ag­nos­tics up­start

8 years ago
Startups

Sen­ti sci­en­tif­ic co-founder Wil­son Wong de­signs the SUPRA — a new, high per­for­mance mod­el CAR-T

8 years ago
People
Discovery

Achao­gen earns $12M award for next-gen an­tibi­otics; En­do ac­quires Som­er­set for $190M

8 years ago
News Briefing
First page Previous page 1040104110421043104410451046 Next page Last page
A service from the Financial Times